Drug companies, as opposed to healthcare agencies, are starting to offer case management to patients (New York Times ), since it is so much in their financial interests that patients continue on their medications as long as possible.

Just as it is so much the function of pharmaceutical company drug representatives to spin the advantages of their products to susceptible doctors, will these case managers begin spinning clinical updates on their patients to their attending physicians in the service of getting the patients on higher doses or longer durations of their companies’ prescriptions?